Table 1
The primer sequences and PCR product length of the target genes
| Gene/Accession number | Primer sequence | Fragment size (bp) |
|---|---|---|
| BLT2 | Forward 5′- TTCCTCATGCGGCTCTTT -3′ | |
| NM_001191287 | Reverse 5′- CCCAACCCTGACTATCCTT -3′ | 163 bp |
| MMP-2 | Forward 5′- AACGCCATCCCTGATAACC-3′ | |
| NM_174745 | Reverse 5′- TCACGCTCTTCAGACTTTGGT-3′ | 115 bp |
| MMP-9 | Forward 5′-GCCCATTAGCACGCACGAC-3′ | |
| NM_174744 | Reverse 5′-GTAGCCCACATAGTCCACCTGA-3′ | 118 bp |
| β-actin | Forward 5′-TCACCAACTGGGACGACA-3′ | |
| NM_173979.3 | Reverse 5′-GCATACAGGGACAGCACA-3′ | 206 bp |
Fig. 1
Ultrastructure of endometrial lamina propria mast cells
A – experimental group; B – control group (arrows indicate mast cell nuclei)
Table 2
Substance P (SP), vasointestinal peptide (VIP) and leukotriene B4 (LTB4) concentrations in the endometrium
| Parameter | Control group | Experimental group | P-value |
|---|---|---|---|
| SP, ng/mL | 308.12 ± 9.72 | 1258.06 ± 128.88* | P < 0.01 |
| VIP, ng/mL | 1667.34 ± 153.40 | 615.73 ± 70.50* | P < 0.01 |
| LTB4, pg/mL | 23.14 ± 1.12 | 78.84 ± 12.55* | P < 0.01 |
Fig. 2
Expression of leukotriene B4 receptor 2 (BLT2), matrix metalloproteinase (MMP)-2 and MMP-9 mRNA by real-time quantitative PCR
* – P < 0.05 for significant difference versus the control group